Ekso Bionics Holdings, Inc.

Greetings. Welcome to the ExoBionics fourth quarter 2021 financial results call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to your host, Matt Steinberg, FinPartners. Thank you. You may begin.

Thank you, operator. And thank you all for participating in today's call. Joining me from Exobionics are Stephen Sherman, Chairman and Chief Executive Officer, Scott Davis, President and Chief Operating Officer, Jack Glenn, Chief Financial Officer, and Bill Shaw, Chief Commercial Officer. Earlier today, Exobionics released financial results for the quarter and year ended December 31st, 2021. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements, including statements regarding our business strategy, future financial or operating expectations, or our expectations of the regulatory landscape governing our products and operations are based upon management's current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our businesses, please see our filings with the Securities and Exchange Commission. XO disclaims any intention or obligation, except as required by law, to update or revise any financial or operational projections or regulatory outlook or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the broadcast today, February 24th, 2022. I will now turn the call over to ExoBionics Chairman and CEO, Steven Sherman.

Thank you, Matt, and thank you, everyone, for joining us today. I am pleased to participate on my first conference call as ExoBionics' new Chief Executive Officer. and I will be working in tandem with our experienced leadership team. I've been EXOS chairman, I'm an early investor, and I have participated in follow-on capital raises. My reputation is one of the serial entrepreneur. I have the drive, I have the confidence, and I have the experience and the belief that we will realize the value of EXOS assets. XO is a leader in early-to-market wearable robotic solutions for medical rehabilitation and workplace safety. Under our leadership, we will focus on strengthening our core business. Now, we'll turn the call over to our new president and chief operating officer, Scott Davis. Thank you, Stephen.